参考文献/References:
[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [J]. CACancer J Clin, 2013, 63(1): 11-30.
[2] KoppenolWH, Bounds PL, Dang CV. Otto warburg's contributionsto current concepts of cancer metabolism [J]. Nat Rev Cancer,2011, 11(5): 325-337.
[3] Hanahan D, Weinberg RA. Hallmarks of cancer: the nextGeneration[J]. Cell, 2011, 144(5): 646-674.
[4] Vander Heiden MG, Cantley LC, Thompson CB. Understandingthe warburg effect: the metabolic requirements of cell proliferation[J]. Science, 2009, 324(5930): 1029-1033.
[5] Schulze A, Harris AL. How cancer metabolism is tuned forproliferation and vulnerable to disruption [J]. Nature, 2012, 491(7424): 364-373.
[6] Hilvo M, Denkert C, Lehtinen L, et al. Novel theranosticopportunities offered by characterization of altered membranelipid metabolism in breast cancer progression [J]. Cancer Res,2011, 71(9): 3236-3245.
[7] Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fattyacid oxidation in the limelight [J]. Nat Rev Cancer, 2013, 13(4):227-232.
[8] Locke JA, Wasan KM, Nelson CC, et al. Androgen-mediatedcholesterol metabolism in LNCaP and PC-3 cell lines is regulatedthrough two different isoforms of acyl-coenzyme A:CholesterolAcyltransferase (ACAT)[J]. Prostate, 2008, 68(1): 20-33.
[9] Cai C, Balk SP. Intratumoral androgen biosynthesis in prostatecancer pathogenesis and response to therapy [J]. Endocr RelatCancer, 2011, 18(5): R175-82.
[10] Ghosh S. Early steps in reverse cholesterol transport: cholesterylester hydrolase and other hydrolases [J]. Curr Opin EndocrinolDiabetes Obes, 2012, 19(2): 136-141.
[11] Pelton K, Freeman MR, Solomon KR. Cholesterol and prostatecancer[J]. Curr Opin Pharmacol, 2012, 12(6): 751-759.
[12] Leon CG, Locke JA, Adomat HH, et al. Alterations in cholesterolregulation contribute to the production of intratumoral androgensduring progression to castration-resistant prostate cancer in amouse xenograft model[J]. Prostate, 2010, 70(4): 390-400.
[13] Hu YW, Yang JY, Ma X, et al. A lincRNA-DYNLRB2-2/GPR119/GLP-1R/ABCA1-dependent signal transductionpathway is essential for the regulation of cholesterol homeostasis[J]. J Lipid Res, 2014, 55(4): 681-697.
[14] Locke JA, Guns ES, LehmanML, et al. Arachidonic acid activationof intratumoral steroid synthesis during prostate cancerprogression to castration resistance [J]. Prostate, 2010, 70 (3):239-251.
[15] Murtola TJ, Tammela TL, Lahtela J, et al. Cholesterol-loweringdrugs and prostate cancer risk: a population-based case-controlstudy [J]. Cancer Epidemiol Biomarkers Prev, 2007, 16 (11):2226-2232.
[16] Magura L, Blanchard R, Hope B, et al. Hypercholesterolemia andprostate cancer: a hospital-based case-control study [J]. CancerCauses Control, 2008, 19(10): 1259-1266.
[17] Bhindi B, Locke J, Alibhai SM, et al. Dissecting the associationbetween metabolic syndrome and prostate cancer risk: analysis ofa large clinical cohort[J]. Eur Urol, 2015, 67(1): 64-70.
[18] Pelton K, Freeman MR, Solomon KR. Cholesterol and prostatecancer[J]. J Cell Biochem, 2012, 12(6): 754-769.
[19] Moon H, Ruelcke JE, Choi E, et al. Diet-inducedhypercholesterolemia promotes androgen-independent prostatecancer metastasis via IQGAP1 and caveolin-1 [J]. Oncotarget,2015, 6(10): 7438-7453.
[20] Platz EA, Till C, Goodman PJ, et al. Men with low serumcholesterol have a lower risk of high-grade prostate cancer in theplacebo arm of the prostate cancer prevention trial [J]. CancerEpidemiol Biomarkers Prev, 2009, 18(11): 2807-2813.
[21] Platz EA, Leitzmann MF, Fisvanathan KA, et al. Statin drugs andrisk of advanced prostate cancer [J]. J Natl Cancer Inst, 2006, 98(24): 1819-1825.
[22] Morote J, Celma A, Planas J, et al. Role of serum cholesterol andstatin use in the risk of prostate cancer detection and tumoraggressiveness[J]. Int J Mol Sci, 2014, 15(8): 13615-13623.
[23] Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, etal. Lack of effect of lowering LDL cholesterol on cancer:meta-analysis of individual data from 175,000 people in 27randomised trials of statin therapy [J]. PloS one, 2012, 7 (1):e29849.
[24] Mostaghel EA, Solomon KR, Pelton K, et al. Impact of circulatingcholesterol levels on growth and intratumoral androgenconcentration of prostate tumors [J]. PLoS One, 2012, 7 (1):e30062.
[25] Zhuang L, Kim J, Adam RM, et al. Cholesterol targeting alterslipid raft composition and cell survival in prostate cancer cells andxenografts[J]. J Clin Invest, 2005, 115(4): 959-968.
[26] Sherwin RW, Wentworth DN, Cutler JA, et al. Serum cholesterollevels and cancer mortality in 361,662 men screened for theMultiple Risk Factor Intervention Trial [J]. JAMA, 1987, 257(7):943-948.
[27] Keys A, Aravanis C, Blackburn H, et al. Serum cholesterol andcancer mortality in the Seven Countries Study [J]. Am JEpidemiol, 1985, 121(6): 870-883.
[28] Solomon KR, Freeman MR. The complex interplay betweencholesterol and prostate malignancy [J]. Urol Clin North Am, 2011, 38(3): 243-259.
[29] Santos CR, Schulze A. Lipid metabolism in cancer [J]. FEBS J,2012, 279(15): 2610-2623.
[30] Menendez JA, Lupu R. Fatty acid synthase and the lipogenicphenotype in cancer pathogenesis [J]. Nat Rev Cancer, 2007, 7(10): 763-777.
[31] Migita T, Ruiz S, Fornari A, et al. Fatty acid synthase: a metabolicenzyme and candidate oncogene in prostate cancer [J]. J NatlCancer Inst, 2009, 101(7): 519-532.
[32] Swinnen JV, Esquenet M, Goossens K, et al. Androgens stimulatefatty acid synthase in the human prostate cancer cell line LNCaP[J]. Cancer Res, 1997, 57(6): 1086-1090.
[33] Swinnen JV, Van Veldhoven PP, Esquenet M, et al. Androgensmarkedly stimulate the accumulation of neutral lipids in thehuman prostatic adenocarcinoma cell line LNCaP [J].Endocrinology, 1996, 137(10): 4468-4474.
[34] Hager MH, Solomon KR, Freeman MR. The role of cholesterol inprostate cancer [J]. Curr Opin Clin Nutr Metab Care, 2006, 9(4):379-385.
[35] Pommier AJ, Alves G, Viennois E, et al. Liver X receptoractivation downregulates AKT survival signaling in lipid rafts andinduces apoptosis of prostate cancer cells [J]. Oncogene, 2010, 29(18): 2712-2723.
[36] Brown MS, Goldstein JL. The SREBP pathway: regulation ofcholesterol metabolism by proteolysis of a membrane-boundtranscription factor[J]. Cell, 1997, 89(3): 331-340.
[37] Ettinger SL, Sobel R, Whitmore TG, et al. Dysregulation of sterolresponse element-binding proteins and downstream effectors inprostate cancer during progression to androgen independence [J].Cancer Res, 2004, 64(6): 2212-2221.
[38] Locke JA, Nelson CC, Adomat HH, et al. Steroidogenesisinhibitors alter but do not eliminate androgen synthesismechanisms during progression to castration-resistance in LNCaPprostate xenografts [J]. J Steroid Biochem Mol Biol, 2009, 115(3-5): 126-136.
[39] Twiddy AL, Leon CG,Wasan KM. Cholesterol as a potential targetfor castration-resistant prostate cancer[J]. Pharm Res, 2011, 28(3):423-437.
[40] Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesisactivates androgen receptor in castration-resistant prostate cancerand is upregulated by treatment with CYP17A1 inhibitors [J].Cancer Res, 2011, 71(20): 6503-6513.
[41] Stanbrough M, Bubley GJ, Ross K, et al. Increased expression ofgenes converting adrenal androgens to testosterone inandrogen-independent prostate cancer [J]. Cancer Res, 2006, 66(5): 2815-2825.
[42] Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase byintratumoral de novo steroidogenesis during progression ofcastration-resistant prostate cancer [J]. Cancer Res, 2008, 68(15):6407-6415.
[43] Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance ofintratumoral androgens in metastatic prostate cancer: a mechanismfor castration-resistant tumor growth[J]. Cancer Res, 2008, 68(11):4447-4454.
[44] Dillard PR, Lin MF, Khan SA. Androgen-independent prostatecancer cells acquire the complete steroidogenic potential ofsynthesizing testosterone from cholesterol [J]. Mol CellEndocrinol, 2008, 295(1/2): 115-120.
[45] Adlakha YK, Khanna S, Singh R, et al. Pro-apoptoticmiRNA-128-2 modulates ABCA1, ABCG1 and RXRαexpression and cholesterol homeostasis [J]. Cell Death Dis, 2013,4: e780.
[46] Yue S, Li J, Lee SY, et al. Cholesteryl ester accumulation inducedby PTEN loss and PI3K/AKT activation underlies human prostatecancer aggressiveness[J]. Cell Metab, 2014, 19(3): 393-406.
[47] Sonn GA, Aronson W, Litwin MS. Impact of diet on prostatecancer: a review [J]. Prostate Cancer Prostatic Dis, 2005, 8 (4):304-310.
[48] Mulholland DJ, Tran LM, Li Y, et al. Cell autonomous role ofPTEN in regulating castration-resistant prostate cancer growth[J].Cancer Cell, 2011, 19(6): 792-804.
[49] Zhuang L, Lin J, Lu ML, et al. Cholesterol-rich lipid rafts mediateakt-regulated survival in prostate cancer cells [J]. Cancer Res,2002, 62(8): 2227-2231.
[50] Thysell E, Surowiec I, H?rnberg E, et al. Metabolomiccharacterization of human prostate cancer bone metastases revealsincreased levels of cholesterol[J]. PLoS One, 2010, 5(12): e14175.[0